Accent Therapeutics
PrivateLast Round
Series C
Jan 23, 2024
Total Funding Raised
$178M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Accent Therapeutics is a biopharmaceutical company that develops small molecule precision oncology therapies targeting RNA-modifying proteins.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Accent Therapeutics Comparables
Compare Accent Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| EPICS Therapeutics | 86% | |
| STORM Therapeutics | 85% | |
| Remix Therapeutics | 84% |
Accent Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jan 23, 2024 | ||||
| Series B | Apr 23, 2020 | ||||
| Series A | Sep 18, 2017 |
Accent Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EcoR1 Capital | Series C, Series A, Series B |
| The Column Group | Series A, Series B, Series C |
| GV | Series B, Series C |
| Mirae Asset | Series C |
| Droia Ventures | Series B, Series C |
| The Chernin Group | Series B, Series C, Series A |
| AbbVie Ventures | Series B, Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors increased 48% MoM.
- Apr 17, 2026
New data for KIF18A inhibitor ATX-295 presented at AACR Annual Meeting.
Accent Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Accent Therapeutics's valuation, stock price, and market status.
Is Accent Therapeutics a public or private company?
Accent Therapeutics is a private company.
What is the current stock price of Accent Therapeutics?
Accent Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Accent Therapeutics worth (valuation)?
Valuation information for Accent Therapeutics is not publicly available.
Can I buy Accent Therapeutics stock?
Accent Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Accent Therapeutics's last funding round?
Accent Therapeutics's most recent funding round was Series C on January 23, 2024.
Who are the main investors in Accent Therapeutics?
Key investors in Accent Therapeutics include EcoR1 Capital, Mirae Asset, The Chernin Group, Mirae Asset Capital Life Science, Atlas Venture.
Will Accent Therapeutics IPO soon?
No public IPO plans have been announced for Accent Therapeutics.
How can I track Accent Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Accent Therapeutics's secondary market activity and sign up for updates.